Streetbeat News

Analyst Ratings

CALC

Oppenheimer analyst Leland Gershell maintains an Outperform rating on CalciMedica (NASDAQ:CALC) with a $14 price target, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:16 pm

RH

Barclays analyst Seth Sigman has maintained an Equal-Weight rating on RH (NYSE:RH) and increased the price target from $293 to $340.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:16 pm

KOD

Barclays analyst Gena Wang maintains an Underweight rating on Kodiak Sciences (NASDAQ:KOD) and raises the price target from $2 to $3.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:15 pm

AGS

JMP Securities analyst Jordan Bender has reiterated a 'Market Outperform' rating on PlayAGS (NYSE:AGS) and maintained a price target of $13. This reaffirms the firm's positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:14 pm

ACHV

Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on Achieve Life Sciences (NASDAQ:ACHV) and maintains an $18 price target.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:14 pm

KNX

Barclays analyst Brandon Oglenski has maintained an Overweight rating on Knight-Swift (NYSE:KNX) but has lowered the price target from $65 to $62.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:14 pm

HTLD

Barclays analyst Brandon Oglenski has maintained an Underweight rating on Heartland Express (NASDAQ:HTLD) and lowered the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:13 pm

ANTX

Oppenheimer analyst Jeff Jones has reiterated a Perform rating on AN2 Therapeutics (NASDAQ:ANTX), maintaining the company's current stock performance outlook.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:13 pm

ACRV

JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on Acrivon Therapeutics (NASDAQ:ACRV) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:13 pm

FI

Barclays analyst David Anderson has maintained an Overweight rating on Fiserv (NYSE:FI) and increased the price target from $165 to $185. This adjustment reflects a positive outlook on Fiserv's stock.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:12 pm